RxDoctor Payments Data

Matthew Stainbrook, DO

Nephrology · du Bois, PANPI 1699714030

Payments from drug & device makers

$12,538in general payments, 2019–2025

Across 416 payments — averaging $30.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Akebia Therapeutics Inc$4K
  • Amgen$883
  • OPKO Pharmaceuticals, LLC$733
  • AstraZeneca$672
  • Travere Therapeutics, Inc.$644
  • Fresenius USA Marketing, Inc.$491
  • plus $5K from 38 others

What the payments were for

  • Speaking & faculty fees$3,22526%
  • Travel & lodging$4934%
  • Food & beverage$8,64869%
  • Education$1721%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,538 in reported general payments places this provider in the 85th percentile of 586 nephrology providers in Pennsylvania.

See all nephrology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$322,235
Medicare patients
745
Services billed
2,630

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TarpeyoBudesonide12$193,183
XphozahTenapanor Hcl51$141,784
FilspariSparsentan12$129,526
VelphoroSucroferric Oxyhydroxide18$106,935
EntrestoSacubitril/Valsartan76$79,404
KerendiaFinerenone46$71,276
LupkynisVoclosporin12$59,948
FarxigaDapagliflozin Propanediol57$59,541
AuryxiaFerric Citrate21$45,854
LokelmaSodium Zirconium Cyclosilicate56$41,970
Repatha SureclickEvolocumab53$32,244
EliquisApixaban30$31,931
VeltassaPatiromer Calcium Sorbitex16$23,407
Sevelamer Carbonate125$21,586
JardianceEmpagliflozin13$16,595

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Calliditas Therapeutics US Inc.Tarpeyo$290$193,18312 claims
Travere Therapeutics, Inc.Filspari$644$129,52612 claims
Fresenius USA Marketing, Inc.Velphoro$491$106,93518 claims
AstraZenecaFarxiga, Lokelma$672$101,511113 claims
NovartisEntresto$274$79,40476 claims
BayerKerendia$475$71,27646 claims
Aurinia Pharma U.S., Inc.Lupkynis$329$59,94812 claims
Akebia Therapeutics IncAuryxia$4,381$45,85421 claims
PfizerEliquis$46$31,93130 claims
Boehringer IngelheimJardiance$219$16,59513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 586 nephrology providers in Pennsylvania.

Other nephrology in du Bois

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →